N30 Pharma picks up $30M in mezzanine funding round to advance cystic fibrosis drug

N30 Pharma picks up $30M in mezzanine funding round to advance cystic fibrosis drug

BOULDER - N30 Pharmaceuticals Inc. , a clinical-stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis, announced it raised $30 million in a mezzanine... Read More

By: InnovatioNews Monday November 24, 2014 0 comments Tags: Boulder, cystic fibrosis, Deerfield Management, Howard Furst, Jennison Associates, N30 Pharmaceuticals, N91115, Sabby Management